No Clinically Significant Drug Interactions Between Xyrem and Egg Retrieval Medications
Based on available evidence, there are no documented pharmacokinetic or pharmacodynamic interactions between sodium oxybate (Xyrem) and the standard medications used during egg retrieval procedures, including gonadotropins (FSH, LH), hCG, GnRH agonists/antagonists (leuprolide, cetrorelix), NSAIDs, acetaminophen, ondansetron, antibiotics, or low-dose steroids.
Key Evidence Assessment
The FDA labeling for Xyrem 1 identifies only one specific drug interaction requiring dose adjustment: divalproex sodium requires a 20% reduction in Xyrem dose 1. Notably absent from the drug label are any warnings or precautions regarding fertility medications, hormonal agents used in assisted reproductive technology, or the supportive medications administered during egg retrieval procedures.
The cetrorelix FDA label 2 similarly contains no warnings about interactions with CNS depressants or sodium oxybate, stating only that "no formal drug interaction studies have been performed with cetrorelix acetate."
Clinical Context and Practical Considerations
Timing and Procedure Safety
The 2024 perioperative guidance for transgender patients undergoing egg retrieval 3 notes that patients may require anesthetic-led sedation for the procedure, but makes no mention of contraindications related to concurrent medications for narcolepsy or other sleep disorders. This suggests standard anesthetic protocols can proceed safely.
Hormonal Stimulation Medications
The fertility treatment guidelines 4 extensively discuss gonadotropins, letrozole, tamoxifen, GnRH agonists, and antagonists without identifying any interactions with CNS medications. The 2018 IUI guidelines 5 detail ovarian stimulation protocols and medication regimens without contraindications for patients on sodium oxybate.
Sedation Considerations
The primary clinical concern is not drug interaction but rather the additive CNS depressant effects during procedural sedation. Xyrem carries an FDA black box warning as a CNS depressant that may cause respiratory depression 6. During egg retrieval under conscious sedation or general anesthesia, inform the anesthesiologist about Xyrem use to allow appropriate monitoring and dose adjustments of sedative agents.
Practical Management Algorithm
- Continue Xyrem as prescribed - No dose adjustment needed for the fertility medications themselves
- Timing consideration: Take Xyrem at the usual nighttime schedule; egg retrieval procedures are typically performed in the morning, allowing adequate time separation
- Anesthesia notification: Ensure the procedural team knows about Xyrem use for appropriate sedation management
- Post-procedure: Resume normal Xyrem dosing schedule that evening unless excessive sedation persists from procedural medications
Important Caveats
- The lack of documented interactions does not mean formal interaction studies have been conducted—rather, no clinically significant problems have emerged in practice
- Xyrem's restricted distribution through the REMS program 7, 8 ensures close monitoring, which would likely detect any emerging safety signals
- Patients should avoid alcohol and other CNS depressants around the time of egg retrieval due to additive effects with both Xyrem and procedural sedation
The evidence strongly supports that standard egg retrieval protocols can proceed safely in patients taking Xyrem, with the sole requirement being appropriate communication with the anesthesia team regarding CNS depressant effects during the procedure itself.